Proffered Paper - GI, colorectal
LINK to Proffered Paper - GI, colorectal
LINK to STREAM (needs an ESMO registration)
396O - Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
The abstract concludes: Pembro monotherapy demonstrated clinically meaningful improvements in HRQoL vs SOC chemotherapy in pts with previously untreated MSI-H/dMMR mCRC.
- Thierry Andre et al. Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
- FDA News Release. FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer. June 29, 2020
397O - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
The abstract concludes: At this preliminary analysis, avelumab plus cetuximab as a rechallenge strategy is effective and well tolerated in chemorefractory RAS/BRAF WT mCRC pts. The final analysis for OS will be presented at the ESMO 2020 congress.
- Erika Martinelli et al. Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
398O - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
The abstract concludes: After curative surgery, the addition of CEA and/or CT does not provide any benefit in 5-year OS, but allows more curative intent secondary surgeries for patients with a more intensive follow-up. Final results of the study will be reported at the meeting. Ref: (1) Lepage Dig Liver Dis. 2015.
Read also ESMO's Daily Reporter News:
399O - Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial
The abstract concludes: Comparing to younger pts, in elderly stage III CC pts treated with an oxaliplatin-based adjuvant therapy, a different treatment tolerability and a potential reduction of benefit was highlighted. Considerations should be made about the patient's general health status, his comorbidities and the management of the expected side effects.
The abstract concludes: Pts with RAS WT mCRC ≥ 70 years old had comparable toxicity and similar efficacy to their younger counterparts when cetuximab was added to DC and adjusting for key confounders. This is the most comprehensive analysis so far on the use of cetuximab in RAS WT older pts.
The abstract concludes: RAS clearance rate in our study is 30.0%, which was higher than that in the previous study. Monitoring RAS mutation status may be useful for the evaluation of treatment and provide insights for following treatment selection. The association between RAS clearance and prognosis in mCRC needs further investigation.